Hypertension in children: An update on treatment strategies

Current Opinion in Pediatrics

Volumn 19, Issue 2, 2007, Pages 170-177

  Seikaly, Mouin G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Children; Hypertension; Treatment

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMLODIPINE; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLOROTHIAZIDE; CLONIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; FELODIPINE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MINIPRES; MINOXIDIL; NIFEDIPINE; PRAZOSIN; PROPRANOLOL; SPIRONOLACTONE; UNCLASSIFIED DRUG; VASODILATOR AGENT; VERAPAMIL; ZESTERIL;

ALGORITHM; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DECISION MAKING; DIET THERAPY; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MORTALITY; NAUSEA; PARESTHESIA; PEDIATRICS; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA;

ANTIHYPERTENSIVE AGENTS; CHILD; HUMANS; HYPERTENSION; RISK REDUCTION BEHAVIOR;

EID: 34247603173     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32801da292     Document Type: Review

References (63)

1. Ezzati M, Lopez AD, Rodgers A, et al., Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
2. Sorof JM, Lai D, Turner J. Overweight, ethnicity, and the prevalence of hypertension in school age children. Pediatrics 2004; 113:475-482.
3. Lauer RM, Clarke WR. Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics 1989; 83:633-642.
4. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: The Bogalusa Heart Study. N Eng J Med 1998; 338:1650-1656.
5. McGill HC, McMahan CA, Zieske AW. Effects of nonlipid risk factors on atherosclerosis in youth with favorable lipoprotein profile. Circulation 2001; 103:1546-1550.
6. Weaver MG, Park MK, Lee DH. Differences in blood pressure levels obtained by auscultatory and oscillometric methods. Am J Dis Child 1990; 144:911-914.
7. Horan MJ, Falker B, Kimm YS, et al. Report of the Second Task Force on Blood Pressure Control in Children: 1987. Pediatrics 1987; 79:1-24.
8. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356:1955-1964.
9. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.
10. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
11. Bakris GL, Textor SC. Hypertension Nephrology Self Assessment Program 2005; 4:75-109.
12. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555-576.
13. Berenson GS, Frank GC, Farris RP. Management of the mildly hypertensive youth: can adult hypertensive disease be prevented. In: Loggie JMH, Horan AB, Gruskin AB, et al. (editors). Proceedings of a Symposium of the Workshop on Juvenile Hypertension. Bethesda, Maryland; 1983. pp. 387-407.
14. Chobanian AV, Bakris GI, Black HR, et al. National Heart, Lung and Blood Pressure Institute Joint National Commission on Prevention, Detection, Evaluation and Treatment of High Blood Pressure; National High Blood Pressure Education Program Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC7 report. JAMA 2003; 289:2560-2572.
15. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for cardiovascular disease among adults previously diagnosed with diabetes. JAMA 2004; 291:335-342.
16. Lazarus JM, Bourgoignie IJ, Buckalew VM, et al. Achievement and safety of low BP goal in chronic renal disease. The modification of Diet in Renal disease Study Group. Hypertension 1997; 29:641-650.
17. Hasabe N, Kido S, Ido A, Kenjoiro K. Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res 2002; 25:381-387.
18. Kannel WB, Wilson PWF, Nam B, et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol 2004; 94:380-383.
19. Adelman MH. Commentary on 'How far should blood pressure be lowered? What is the role of the J-curve?' Lennart Hannson. Am J Hypertens 1990; 3:730-732.
20. Seikaly MG, Atiyeh B, Brandis M. Hypertension. In: Eichenwald HF, Stroder J, editors. Pediatric therapy, 3rd ed. St Louis, Missouri: Mosby-Year Book, Inc.; 1993. pp. 321-325.
21. Mitsnefes M. Hypertension in children and adolescents. Pediatr Clin N Am 2006; 53:493-512.
22. Still JL, Cottom D. Severe hypertension in childhood. Arch Dis Child 1967; 42:34-39.
23. Kaplan NM. New approaches to the therapy of mild hypertension. Am J Cardiol 1983; 51:621-627.
24. Textor SC. Management of mild hypertension. Mayo Clinic Proc 1989; 64:1543-1552.
25. Hofman A, Grobee DE. Nonpharmacological intervention in primary hypertension in childhood. Clin Exp Hypertens A 1986; 8:813-822.
26. Data Coordinating Centers. The hypertension prevention trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990; 50: 153-162.
27. Sinaiko AR, Gomez-Marin O, Prineas RJ. Effect of low sodium diet or potassium supplementation on adolescent blood pressure. Hypertension 1993; 21:989-994.
28. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350:2362-2374.
29. Sacks FM, Svetkey LP, Vollmer WM, et al. The DASH-sodium collaborative research group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001; 344:3-10.
30. Committee on Sports Medicine and Fitness. Athletic participation by children and adolescents who have systemic hypertension. Pediatrics 1997; 99:637-638.
31. Weinberger MH, Cohen SJ, Miller JZ, et al. Dietary sodium restriction as adjunctive treatment of hypertension. JAMA 1989; 259:2561-2565.
32. Grobbee DE, Hofman A, Roelandt JT, et al. Sodium restriction and potassium supplementation in young people with mildly elevated blood pressure. J Hypertension 1987; 5:115-119.
33. McCarron DA, Morris CD. The calcium deficiency hypothesis of hypertension. Ann Intern Med 1987; 107:919-922.
34. Stern B, Heyden S, Miller D, et al. Intervention study in high school students with elevated blood pressures. Nutr Metab 1980; 24:137-147.
35. Rocchini A, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321: 580-585.
36. Higgins MW. Weight and obesity as predictors of blood pressure and hypertension. In: Loggie JMH, Horan AB, Gruskin AB, et al., editors. Proceedings of a Symposium of the Workshop on Juvenile Hypertension. Bethesda, Maryland; 1983. pp. 125-144.
37. Laird WP, Fixler DE, Huffines FD. The cardiovascular response to isometric exercise in normal adolescents. Circulation 1979; 59:651-658.
38. He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on the incidence of hypertension. Hypertension 2000; 35:544-549.
39. Flynn JT. Hypertension in adolescents. Adolesc Med 2005; 16:11-29. A comprehensive review of the management of hypertension in children.
40. Andrews CD, Essex A. Captopril suspension. Pharmaceut J 1986; 2:734-735.
41. Allen LV, Erickson MA. Stability of alprazolam, chloroquine phosphate, cisapride, enalapril maleate, and hydralazine hydrochloride in extemporaneously compounded-oral liquids. Am J Health Syst Pharm 1998; 55:1915-1920.
42. Atenlol 2-mg/m/ oral liquid. Int J Pharm Compound 2004; 83:215.
43. Allen LV, Erickson MA. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1996; 53:2304-2309.
44. Nahata MC, Hipple TF, editors. Pediatric drug formulations. 4th ed. Cincinnati, OH: Harvey Whitney Books; 2000. p. 83.
45. Levinson ML, Johnson CE. Stability of an extemporaneously compounded clonidine hydrochloride oral liquid. Am J Hosp Pharm 1992; 49:122-125.
46. Allen LV, Erickson MA. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1996; 53:2073-2078.
47. Alexander KS, Pudipeddi M, Parker GA. Stability of hydralazine hydrochloride syrup compounded from tablets. Am J Hosp Pharm 1993; 50:683-686.
48. Gifford RW Jr, Borazvinian RA. Traditional first-line therapy overview of medical benefits and side effects. Hypertension 1989; 13 (Suppl I):I119-I124.
49. Black HR. Choosing initial therapy for hypertension: a personal view. Hypertension 1989; 13 (Suppl I):I149-I153.
50. Raij L, Shultz PJ, Tolins JP. Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors. J Hypertens 1989; 7 (Suppl 7):S33-S37.
51. Rodicio JL, Praga M, Alcazar JM, et al. Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans. J Hypertens 1989; 7 (Suppl 7):S43-S47.
52. Tanaka H, Suzuki K, Nakahata T, et al. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin: a nephropathy. Pediatr Int 2004; 46:576-579.
53. Martin MFR, Mckenno F, Bird HA, et al. Captopril: a new treatment for rheumatoid arthritis. Lancet 1984; 1:1325-1328.
54. Laragh JH. New angiotensin converting enzyme inhibitors: their role in the management of hypertension. Am J Hypertens 1990; 3:257S-265S.
55. Sinaiko AR, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril in children and adolescents. Clin Exp Theory Pract 1986; A8: 829-839.
56. Shahinfar S, Cano F, Soffer BA, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005; 18:183-190.
57. Ellis D, Moritz ML, Vats A, Janosky JE. Antihypertensive and renoprotective efficacy and safety of losartan: a long-term study in children with renal disorders. Am J Hypertens 2004; 17:928-935.
58. Ellis D, Vats A, Moritz ML, Reitz S, et al. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 2003; 143:89-97.
59. White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr Nephrol 2003; 18:1038-1043.
60. Aust NZJ. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynaecol 1998; 38:306-311.
61. Alwan S, Polifika JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005; 73:123-130.
62. Yiu V, Orrbine E, Rosychuk RJ, et al. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 2004; 19:644-650.
63. Bowely DL, Monica I, Scolink D, et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol 1996; 50:147-148.